Acute Megakaryoblastic Leukemia (AMKL) is a subtype of acute myeloid leukemia (AML) that morphologically resembles abnormal megakaryoblasts. While extremely rare in adults, pediatric cases comprise between 4 and 15% of newly diagnosed AML patients. AMKL in children with Down syndrome (DS) is characterized by a founding GATA1 mutation that cooperates with trisomy 21, followed by the acquisition of additional somatic mutations in epigenetic and kinase signaling genes. Clinically this manifests as a transient myeloproliferative disease (TMD) in the first year of life, followed by spontaneous resolution and the subsequent development into AMKL in a small fraction of patients with a latency of one to five years. Outcomes in DS-AMKL are excellent, with greater than 80% overall survival.
Introduction
Acute Megakaryoblastic Leukemia (AMKL) is a subtype of acute myeloid leukemia (AML) characterized by abnormal megakaryoblasts that express platelet-specific surface glycoprotein.
Bone marrow biopsy frequently demonstrates extensive myelofibrosis, often making aspiration in these patients difficult. AMKL is extremely rare in adults, occurring in only 1% of AML patients 1 . This is in contrast to children, where it comprises between 4 and 15% of AML patients 2, 3 . In pediatrics, the disease is divided into two major subgroups: AMKL in patients with DS (DS-AMKL) and AMKL in patients without DS (non-DS-AMKL). AMKL is the most frequent type of AML in children with DS, and the incidence in these patients is 500-fold higher
For personal use only. on April 4, 2017 . by guest www.bloodjournal.org From than in the general population 4 . In contrast to non-DS-AMKL, leukemic cells not only carry megakaryocytic cell surface markers, but erythroid markers as well resulting in a distinct World Health Organization classification "myeloid leukemia in Down syndrome" 5 . Somatic mutations in GATA1 are found in almost all cases of DS-AMKL and precede the development of leukemia as indicated by their presence in patients with transient myeloproliferative disease (TMD) in the neonatal period [6] [7] [8] [9] [10] [11] . DS-AMKL is not only biologically distinct, but clinically distinct as well, with superior outcomes compared to non-DS-AMKL [12] [13] [14] [15] . Pediatric non-DS-AMKL is a heterogenous group of patients, a significant proportion of which carry chimeric oncogenes including RBM15-MKL1, CBFA2T3-GLIS2, NUP98-KDM5A, and MLL gene rearrangements 16, 17 . Unfortunately, the outcome of non-DS-AMKL is generally poor, with lower event free survival than DS-AMKL and pediatric AML, even in the face of intensified treatment 2, 18 .
DS-AMKL
Transient Myeloproliferative Disease DS-AMKL is associated with a hematologic disorder in infancy, termed transient myeloproliferative disease (TMD). In this disorder, a clonal population of megakaryoblasts accumulate in the peripheral blood. These blasts are phenotypically indistinguishable from AMKL leukemic blasts and in the majority of cases, remission is spontaneous within 3 months in the absence of treatment. In approximately 20% of TMD cases, patients will go on to develop MDS and/or AMKL 19 . TMD is felt to originate in utero, as an identical mutation in GATA1, the genetic lesion associated with TMD, was found to be present at birth in twins that suffered from TMD 20 . Further evidence came with the analysis of archived autopsy specimens from DS patients that identified GATA1 mutations in two fetal liver specimens 21 . A subsequent study screening Guthrie cards from 585 DS infants identified GATA1 mutations in 3.8% of their cohort, confirming the presence of this lesion in a subset of patients at birth 22 . The frequency of this lesion in newborn DS patients was found to be significantly higher in a study that utilized next [28] [29] [30] [31] [32] . In contrast, the mutations detected in DS patients consist of short deletions, insertions, and point mutations within exon 2 that introduce a premature stop codon 7 . This shorter mutant protein retains the ability to bind DNA and interact with its cofactor, but lacks the transcriptional activation domain and hence has reduced transactivation potential 7 . To model TMD, a knock-in line of mice expressing a truncated form of GATA1 was generated and found to result in hyperproliferative megakaryocytic progenitors in the yolk sac and fetal liver that disappeared by the end of gestation 33 . A separate group crossed mice transgenic for a truncated form of GATA1 to the GATA1 knockout strain 34 . During the neonatal period, mice accumulate immature megakaryocytic progenitors in the liver that disappear during weaning of the pups. Regardless of the difference in timing, these models serve to validate that a truncated GATA1 protein is able to confer a proliferative advantage, generating a pool of precursors that have the potential to develop into a leukemic population. The mechanism whereby truncated GATA1 is able to induce a preleukemic state is not fully elucidated, although genome-wide chromatin immunoprecipitation sequencing (ChIP-seq) of genes bound by GATA1 merged with expression profiling revealed a large number of activated and repressed genes respectively that were occupied by the GATA1 protein 35 . Further studies have shown that GATA1 is able to activate lineage specific genes and repress progenitor maintenance genes depending on the 57 . It has been suggested that together, they play a role in the establishment and maintenance of topological domains 58 . Their disruption thus has the potential to significantly disrupt chromatin architecture and in doing so, gene expression. Interestingly, GATA1 has been found to co-occupy genes with the RAD21 cohesin component as well as CTCF in adult pro-erythrocytes (796 and 656 target genes respectively) providing direct evidence for cooperative effects between these genes 59 .
EZH2, the catalytic subunit of the Polycomb repressive complex 2 (PRC2) was the most growth in laboratory assays [63] [64] [65] . Over-expression of one of the DS-AMKL associated JAK3
activating mutations has been shown to result in a lethal megakaryocyte progenitor expansion in a subset of mice, further supporting this signaling pathway in AMKL 64 .
Non-DS-AMKL

RBM15-MKL1
The t(1;22) translocation and its association with AMKL in infants was initially identified in a cohort of 252 children with AML accrued over a 24 month period 66 . In this report, no cases of t(1;22) were identified in a concurrent pediatric ALL cohort of 2382 cases and the translocation was exclusively found in patients with AMKL, all of which were less than 1 year of age. This fusion was very specific for infant AMKL as the 22 other infants with AML that lacked the translocation had a different phenotypic subtype. Further, the remaining 12 non-DS-AMKL cases carried no recurring chromosomal abnormalities and were all older in age. Others have since confirmed this association, but it wasn't until 10 years after the initial report that the genes involved in the translocation were characterized [67] [68] [69] [70] . Two groups simultaneously identified the genes on chromosomes 1 and 22 involved in the translocation, RBM15 (also known as OTT)
and MKL1 (also known as MAL) respectively 67, 70 . Since their initial cloning, much has been learned about the function of the genes and a role of the translocation in inducing leukemia has been demonstrated in a knock-in mouse model 71 .
MKL1 is a transcriptional coactivator for serum response factor (SRF), a transcription factor that regulates the expression of genes involved in cell growth, proliferation, differentiation, and genes that control the actin cytoskeleton 72 . In serum starved cells MKL1 associates with G actin monomers and is retained in the cytoplasm. Following serum stimulation and Rho-mediated actin polymerization, G actin pools are depleted and MKL1 translocates to the nucleus, associating with SRF to activate gene transcription 73, 74 . During murine megakaryocyte differentiation, Mkl1 is upregulated. Consistent with this, Mkl1 knockout mice have an increased percentage of megakaryocytic progenitors, a decrease in mature megakaryocytes, as well as dysplastic megakaryocytes 75, 76 . RBM15 belongs to the Spen family of proteins and encodes a protein containing three amino-terminal RNA recognition motifs that bind to nucleic acids and a 1 0 C-terminal SPOC domain that is thought to interact with the SMRT and NCoR corepressor complexes as well as RBPJ, a transcription factor downstream of Notch signaling 77, 78 . Rbm15 knockout mice are embryonic lethal, thus to evaluate the effect of this protein on hematopoiesis, conditional knockout mice have been generated 79, 80 . These mice have a block in B lymphopoiesis and expansion of the myeloid, megakaryocytic, and progenitor compartments 75, 79 . The fusion of MKL1 to RBM15 deregulates the normal intracellular localization of MKL1 such that it is becomes constitutively localized to the nucleus resulting in SRF activation even in the absence of stimuli 81 . In addition to the SRF transcriptional program, the fusion also aberrantly activates RBPJ transcriptional targets. While both transcription programs have been shown to be deregulated by the fusion gene, the degree to which they contribute to transformation is still unclear.
In studies done to address the role of the RBM15-MKL1 chimeric gene in AMKL, knock-in mice were engineered to express the chimeric oncogene under control of the endogenous Rbm15 promoter 71 . These mice display abnormal fetal and adult hematopoiesis with a small fraction developing AMKL between 18-24 months of age 71 . Using this mouse model, the authors present data to support RBM15-MKL1 activated RBPJ mediated transcriptional activity that leads to upregulation of the Notch pathway 71 . Consistent with this, Rbm15 has been shown to modulate Notch induced transcription in a cell type specific manner 82 . Given that only a fraction of mice developed overt AMKL at a late age, the authors reasoned that cooperating oncogenic events were required to induce AMKL. . Furthermore, the CBFA2T3-GLIS2 fusion gene conferred a poor prognosis, a finding which has since been confirmed 16, 17, 85 . This fusion was subsequently reported to also occur at a low frequency in pediatric cytogenetically normal AML 85 .
Expression of CBFA2T3-GLIS2 in Drosophila and murine hematopoietic cells induced bone morphogenic protein (BMP) signaling, a pathway not previously implicated in AML, and resulted in a marked increase in the self-renewal capacity of hematopoietic progenitors 16 . The contribution of BMP signaling to self-renewal in CBFA2T3- CBFA2T3-GLIS2 expressing cells remained growth factor dependent in vitro suggesting that cooperating mutations in growth factor signaling pathways are likely required for full leukemic transformation. Moreover, transplantation of CBFA2T3-GLIS2 transduced bone marrow cells into syngeneic recipients failed to induce overt leukemia, consistent with a requirement for cooperative mutations. Failure to induce leukemia in mice as a single lesion has been previously reported for other chimeric genes that confer the ability to serially replate in colony forming assays, including AML1-ETO 86 . Overall, the total burden of somatic mutations in our cohort was significantly lower in the CBFA2T3-GLIS2 expressing cases for which germline DNA was available compared to non-DS-AMKL that lacked this fusion gene (7.2 ± 3.6 versus 16.6 ± 5.1, p=0.009) 16 . Of the fifteen CBFA2T3-GLIS2 positive cases analyzed to date, five carried lesions in either a Janus Kinase (JAK) gene and/or a somatic amplification of the DS critical region on chromosome 21. However, the majority of cases do not contain an identifiable cooperating lesion (unpublished data and 16 ). As these cases have been interrogated by single nucleotide polymorphism arrays, exome, and/or transcriptome sequencing, a more thorough whole genome approach may help to further delineate the additional events required by this fusion oncogene. Whole genome sequencing would allow the identification of somatic mutations in noncoding intergenic regions that are oncogenic. Examples of these types of lesions include TERT promoter mutations and super-enhancer formation upstream of the TAL1 oncogene, as identified in melanoma and T cell acute lymphoblastic leukemia respectively 87, 88 .
Lower Frequency Fusion Events
In addition to CBFA2T3-GLIS2, we identified approximately 8% of our pediatric cohort to carry the previously described NUP98-KDM5A fusion gene (Figure 3 ) 16 . In parallel with our efforts, de
Rooij and colleagues evaluated a separate non-DS-AMKL cohort for NUP98 fusion events by split-signal fluorescence in situ hybridization and found a similar frequency of 11% 17 . NUP98, a nucleoporin family member with transactivation activity, fused to KDM5A, an H3K4me3 binding PHD finger, was initially described in adult AML 89, 90 . In addition to the previously described NUP98-KDM5A fusion we identified three novel fusion genes expressed in a single case each: GATA2-HOXA9, MN1-FLI1, and NIPBL-HOXB9
( Figure 3) . Each of these chimeric transcripts are predicted to encode a fusion protein that would alter signaling pathways known to play a role in normal hematopoiesis suggesting that
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Several of the genes involved in these translocations play a direct role in normal megakaryocytic differentiation (GATA2 and FLI1), have been previously shown to be involved in leukemogenesis (HOXA9, MN1, HOXB9 ), or are highly expressed in hematopoietic stem cells or myeloid/megakaryocytic progenitors [91] [92] [93] [94] [95] [96] . Genome wide approaches in a larger AMKL cohort are necessary to determine if these fusion genes are recurrent. Current efforts in our laboratories include experiments to determine the ability of these fusion genes to enhance selfrenewal, block differentiation, and induce leukemia in murine model(s) with a focus on the mechanism whereby these processes take place.
Conclusion
Pediatric AMKL is a heterogeneous disease comprised on chimeric oncogenes or truncating 
